BlackRock
OBIO icon

BlackRock’s Orchestra BioMed OBIO Stock Holding History

BlackRock’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
2,510,387
+1,874,673
+295% +$7.67M ﹤0.01% 3634
2026
Q1 		$2.7M Buy
635,714
+4,813
+0.8% +$20.5K ﹤0.01% 4042
2025
Q4 		$2.62M Sell
630,901
-33,432
-5% -$135K ﹤0.01% 4051
2025
Q3 		$1.65M Sell
664,333
-17,016
-2% -$46.9K ﹤0.01% 4152
2025
Q2 		$1.83M Sell
681,349
-1,264,307
-65% -$3.69M ﹤0.01% 4083
2025
Q1 		$8.33M Sell
1,945,656
-33,174
-2% -$165K ﹤0.01% 3409
2024
Q4 		$7.92M Buy
1,978,830
+36,439
+2% +$196K ﹤0.01% 3542
2024
Q3 		$9.98M Buy
1,942,391
+77,418
+4% +$506K ﹤0.01% 3408
2024
Q2 		$15.2M Buy
1,864,973
+423,784
+29% +$2.45M ﹤0.01% 3145
2024
Q1 		$7.6M Sell
1,441,189
-27,579
-2% -$187K ﹤0.01% 3491
2023
Q4 		$13.4M Buy
1,468,768
+138,854
+10% +$948K ﹤0.01% 3242
2023
Q3 		$11.6M Buy
1,329,914
+474,347
+55% +$3.19M ﹤0.01% 3249
2023
Q2 		$5.99M Buy
855,567
+150,892
+21% +$2.29M ﹤0.01% 3650
2023
Q1 		$13.8M Sell
704,675
-85,761
-11% -$993K ﹤0.01% 3153
2022
Q4 		$7.89M Hold
790,436
– – ﹤0.01% 3503
2022
Q3 		$7.83M Sell
790,436
-4,704
-0.6% -$46.6K ﹤0.01% 3551
2022
Q2 		$7.92M Hold
795,140
– – ﹤0.01% 3619
2022
Q1 		$7.88M Sell
795,140
-2,208
-0.3% -$21.8K ﹤0.01% 3713
2021
Q4 		$8.04M Hold
797,348
– – ﹤0.01% 3790
2021
Q3 		$7.88M Hold
797,348
– – ﹤0.01% 3782
2021
Q2 		$8.13M Sell
797,348
-2,652
-0.3% -$27.4K ﹤0.01% 3716
2021
Q1 		$8.95M Hold
800,000
– – ﹤0.01% 3640
2020
Q4 		$10.2M Hold
800,000
– – ﹤0.01% 3346
2020
Q3 		$8.8M Buy
+800,000
New +$8.98M ﹤0.01% 3296

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock's OBIO Position: Q2 2026 in Review

BlackRock increased its Orchestra BioMed (OBIO) stake by 295% in Q2 2026, buying an estimated $7.67M and bringing the position to 2,510,387 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

BlackRock first reported a position in OBIO in Q3 2020 and has held it in 24 quarters since. The position peaked at $15.2M in Q2 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • BlackRock held 2,510,387 shares of Orchestra BioMed worth $10.8M as of Q2 2026.
  • BlackRock bought 1,874,673 Orchestra BioMed shares in Q2 2026, an estimated $7.67M.
  • Orchestra BioMed made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3634 holding.
  • BlackRock first reported a position in Orchestra BioMed in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's Orchestra BioMed position peaked at $15.2M in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.